The content on this site is intended for healthcare professionals only
Dr Paul de Souza from New South Wales, Australia, discusses how close we are to personalising treatment in patients with prostate cancer. He explores what the concept of personalised medicine really means, and the biomarkers being considered in prostate cancer in this regard. He explores the process for biomarker development, and also notes the challenges of personalised care in prostate cancer.
This video is sponsored by an educational grant from Janssen Asia Pacific, a pharmaceutical company of Johnson & Johnson
The added value of integrative medicine
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
ESMO 2024: Optimising the personalisation of prostate cancer treatment
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
Hypofractionated high dose intensity modulated radiotherapy non-inferior for prostate cancer
Overview of the management of HER2-low breast cancer patients
